SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Mannkind Corporation
MNKD 5.590+0.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant1/2/2024 11:09:38 AM
   of 84
 
MannKind has sold a 1% royalty interest in sales of the lung-disease treatment Tyvaso DPI to asset manager Sagard in a deal worth up to $200 million to the biopharmaceutical company.

MannKind on Tuesday said it received an initial $150 million and is eligible for a potential milestone payment of up to $50 million based on sales of the drug.

MannKind in 2018 licensed Tyvaso DPI to United Therapeutics, which began marketing the drug in June 2022 for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

MannKind, which was entitled to a 10% royalty on Tyvaso DPI sales, said it retains a 9% royalty, while Sagard will receive a 1% royalty on Tyvaso DPI sales through 2042.

MannKind, based in Danbury, Conn., reported royalties related to Tyvaso DPI of $51 million for the nine months ended Sept. 30.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News